Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epiderman growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial
Access Status
Fulltext not available
Authors
Eiermann, W.
Pienkowski, T.
Crown, J.
Sadeghi, S.
Chan, Arlene
Saleh, M.
Sehdev, S.
Provencher, L.
Semiglazov, V.
Press, M.
Sauter, G.
Lindsay, M.
Riva, A.
Buyse, M.
Drevot, P.
Taupin, H.
Mackey, J.
Date
2011Type
Journal Article
Metadata
Show full item recordCitation
Eiermann, W. and Pienkowski, T. and Crown, J. and Sadeghi, S. and Chan, A. and Saleh, M. and Sehdev, S. et al. 2011. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epiderman growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. Journal of Clinical Oncology. 29 (29): pp. 3877-3884.
Source Title
Journal of Clinical Oncology